Pfizer

News

CDC backs maternal use of Pfizer’s RSV vaccine

The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect newborns and infants from the virus after an advisor

News

Pfizer’s alopecia drug gets EU nod, chasing Lilly’s Olumiant

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant.

News

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy

Despite a sceptical appraisal by FDA reviewers, Alnylam's Onpattro has been recommended for approval as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM)

News

Vydura is first NICE-backed oral GPCR for acute migraine

Pfizer's Vydura has become the first drug in the oral GPCR receptor antagonist class to be recommended for routine NHS use as a treatment for acute migraine.

News

EU clears review of Xtandi in earlier-stage prostate cancer

The EMA will kick off a review of Astellas and Pfizer's prostate cancer therapy Xtandi in an earlier-stage form of the cancer, which if approved could give the product a l

News

FDA clears new Pfizer, Moderna COVID jabs as cases tick up

The FDA has authorised updated versions of Pfizer/BioNTech and Moderna's mRNA-based COVID-19 vaccines targeting the XBB.1.5 subvariant, in time for the start of a new autu

CDC backs maternal use of Pfizer’s RSV vaccine

Pfizer’s alopecia drug gets EU nod, chasing Lilly’s Olumiant

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy

Vydura is first NICE-backed oral GPCR for acute migraine

EU clears review of Xtandi in earlier-stage prostate cancer

FDA clears new Pfizer, Moderna COVID jabs as cases tick up

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Pfizer

Editor's Picks